Head-To-Head Comparison: Hoth Therapeutics (NASDAQ:HOTH) vs. GelStat (OTCMKTS:GSAC)

GelStat (OTCMKTS:GSAC) and Hoth Therapeutics (NASDAQ:HOTH) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Valuation & Earnings

This table compares GelStat and Hoth Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GelStat	N/A	N/A	N/A	N/A	N/A
Hoth Therapeutics	N/A	N/A	-$7.84 million	($1.33)	-0.74

Volatility and Risk

GelStat has a beta of 2.95, indicating that its share price is 195% more volatile than the S&P 500. Comparatively, Hoth Therapeutics has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.

Insider & Institutional Ownership

7.1% of Hoth Therapeutics shares are held by institutional investors. 20.5% of GelStat shares are held by insiders. Comparatively, 10.6% of Hoth Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations for GelStat and Hoth Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GelStat	0	0	0	0	0.00
Hoth Therapeutics	0	0	3	1	3.25

Hoth Therapeutics has a consensus target price of $4.00, indicating a potential upside of 308.83%. Given Hoth Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Hoth Therapeutics is more favorable than GelStat.

Profitability

This table compares GelStat and Hoth Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GelStat	N/A	N/A	N/A
Hoth Therapeutics	N/A	-89.68%	-82.61%

Summary

Hoth Therapeutics beats GelStat on 5 of the 9 factors compared between the two stocks.

About GelStat

GelStat Corporation, a consumer health care company, engages in the research, development, and marketing of over-the-counter and other non-prescription consumer health care products. Its products include GelStat Migraine, a patented solution used for pain relief from migraine headaches; Chews 2 Lose, an appetite suppressant gum for diet aide; All Natural Speed, an energy supplement product; and GelStat Sleep, a product for relief from sleep disorders and its associated symptoms. The company sells its products to retailers, wholesalers, specialty distributors, and catalog merchandisers both directly and through external sales brokers. GelStat Corporation was founded in 2002 and is headquartered in Palm City, Florida.

About Hoth Therapeutics

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.